Who are CLA (Clarithro+Lanso+Amoxi)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Amoxicillin-Clarithromycin-Lansoprazole.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cla-clarithro-lanso-amoxi.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

CLA (Clarithro+Lanso+Amoxi) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CLA (Clarithro+Lanso+Amoxi) (CLA (Clarithro+Lanso+Amoxi)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination with proton pump inhibitor. Area: Gastroenterology / Infectious Disease.

phase 3 Antibiotic combination with proton pump inhibitor H. pylori bacterial ribosomes (clarithromycin); H. pylori cell wall (amoxicillin); gastric H+/K+-ATPase (lansoprazole) Gastroenterology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

CLA (Clarithro+Lanso+Amoxi) (CLA (Clarithro+Lanso+Amoxi)) — Asofarma de México S.A de C.V.. CLA is a triple-therapy combination that eradicates Helicobacter pylori through dual antibiotic action (clarithromycin and amoxicillin) plus acid suppression (lansoprazole).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CLA (Clarithro+Lanso+Amoxi) TARGET	CLA (Clarithro+Lanso+Amoxi)	Asofarma de México S.A de C.V.	phase 3	Antibiotic combination with proton pump inhibitor	H. pylori bacterial ribosomes (clarithromycin); H. pylori cell wall (amoxicillin); gastric H+/K+-ATPase (lansoprazole)
Amoxicillin-Clarithromycin-Lansoprazole	Amoxicillin-Clarithromycin-Lansoprazole	Fatma Zehra Arvas	marketed	Triple therapy antibiotic combination with proton pump inhibitor	Helicobacter pylori bacterial ribosomes (amoxicillin and clarithromycin); H+/K+-ATPase (lansoprazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination with proton pump inhibitor class)

Asofarma de México S.A de C.V. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CLA (Clarithro+Lanso+Amoxi) — Competitive Intelligence Brief. https://druglandscape.com/ci/cla-clarithro-lanso-amoxi. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab